Luspatercept for first‐line treatment of all LR‐MDS and intermediate risk if SF3B1 mut in Europe. In the UK, only as second‐line treatment. FDA approved for anemia failing an erythropoiesis stimulating agent and requiring two or more RBC units over 8 weeks in adult patients with very low‐ to intermediate‐risk myelodysplastic syndromes with ring‐siderobalsts. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.